Research
Metabolic adaptation
Canagliflozin has shown benefits in reducing progression of renal disease and heart failure in patients with type 2 diabetes.
Canagliflozin may be a beneficial treatment option for managing renal and heart health in diabetic patients.
StrongSupportsmedium confidence
Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor which has shown benefits in reducing progression of renal disease and heart failure in patients with T2D.
Why this rating
The claim is based on a review of literature regarding canagliflozin's effects.
Source
Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date
Brian Tomlinson et al. · Expert Opinion on Pharmacotherapy · 2023
DOI 10.1080/14656566.2023.2276180
reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Metabolic adaptation
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →